

# ADVANCING UNIVERSAL HEALTH COVERAGE IN AFRICA




Universal Health Coverage (UHC) is at the heart of the health-related Sustainable Development Goals (SDGs). It is the foundation for both global health security and the health and well-being of all people throughout their lifetimes.

Africa's health systems are essential in delivering the [UHC2030 action agenda](#). Given Africa's population is expected to double by 2050, achieving UHC today on the continent also ensures that its health systems are strengthened and safeguarded to meet the needs of a growing population.

The innovative pharmaceutical industry has long been committed to partnering across sectors and stakeholders to develop innovative solutions that increase access to diagnosis, treatment, and care. In a year dedicated to UHC, we recognize the need to double down on our collective efforts to accelerate a [sustainable health ecosystem in Africa](#).

THE TOP 10 COUNTRIES IN WHICH OUR COLLABORATIONS ARE ACTIVE



To ensure we move together toward UHC, we engage in synergistic **multistakeholder collaborations** with partners ranging from global and local NGOs to governments and international organizations...

**39** OF OUR COLLABORATIONS INCLUDE MORE THAN ONE IFPMA MEMBER COMPANY

**122** OF OUR PROGRAMS INCLUDE A COLLABORATION WITH MORE THAN ONE TYPE OF PARTNER



AT THE GLOBAL/INTERNATIONAL LEVEL, OUR MOST COMMON PARTNERS ARE:



**Bill & Melinda GATES foundation**

**Bill and Melinda Gates Foundation**  
19 programs

**World Health Organization**

**World Health Organization (WHO)**  
19 programs




**US Agency for International Development (USAID)**  
12 programs

WE COLLABORATE WITH REGIONAL/NATIONAL ORGANIZATIONS, INCLUDING MINISTRIES OF HEALTH IN 21 COUNTRIES



AND WE ENGAGE AT THE LOCAL LEVEL WITH:



**Local NGOs**  
41 programs



**Academia/research institutions**  
67 programs



**Healthcare facilities**  
28 programs

IFPMA also supports several initiatives that promote, buttress, and sustain Africa's health ecosystem, including...



OUR PROGRAMS TARGET A RANGE OF POPULATION GROUPS, INCLUDING:




**People with low incomes**  
47 programs

**Women**  
32 programs

**Children**  
27 programs

WE WORK ACROSS MANY DISEASE AREAS, INCLUDING:



**1 Cancer**  
56 programs

**2 HIV, TB, malaria**  
50 programs


**3 Diabetes**  
26 programs

**4 NTDs**  
21 programs



BEYOND MEDICINE PROVISION, WE SUPPORT COUNTRIES THROUGH HOLISTIC PROGRAMMING...

WE WORK ACROSS PROGRAM STRATEGIES AND USE DIVERSE APPROACHES TO IMPROVE HEALTH, INCLUDING:



- Building health work capacity, including community healthcare workers 72 programs
- Increasing community awareness and linking patients to care 64 programs
- Strengthening health systems, including primary healthcare 60 programs
- Delivering preventative health services 38 programs
- Developing technology and mHealth solutions 15 programs
- Promoting the development, transfer, dissemination, and diffusion of technologies 9 programs

OUR PROGRAMS SUPPORT THE SDGs BEYOND HEALTH, INCLUDING:



**39%** of our programs in Africa support **SDG 5**



**34%** of our programs in Africa support **SDG 9**



**32%** of our programs in Africa support **SDG 10**

ADDRESSING ENVIRONMENT-RELATED SDGs

Innovative pharmaceutical companies are also dedicated to addressing **environment-related SDGs**, including SDG 6 on clean water and sanitation, SDG 12 on responsible production and consumption, and SDG 13 on climate action.

Companies are working on initiatives to reduce carbon emissions across their own operations and value chains, invest in renewable electricity and energy efficiency measures, recycle and cut water use, as well as work on bespoke projects that will positively impact the environment.\*

\*IFPMA member companies are committed to mitigating the health challenges of climate change, however *Global Health Progress* hub ([globalhealthprogress.org](http://globalhealthprogress.org)) does not track efforts toward these SDGs yet.

## UHC2030 PRIVATE SECTOR CONSTITUENCY FIVE COMMITMENTS – IN ACTION IN AFRICA



The private sector is an essential partner in reaching shared global health goals, particularly in low- and middle-income countries whose health systems are under-equipped and over-burdened.

In support of the [UHC2030 action agenda](#), its private sector constituency group issued a [statement](#) in April 2023 to underscore 5 commitments. The innovative pharmaceutical industry is advancing these commitments through collaborations in Africa.

**1** INCORPORATE UHC PRINCIPLES, INCLUDING TO LEAVE NO ONE BEHIND, INTO OUR BUSINESS

**ViiV Healthcare's Positive Action Program:** This program was originally established in 1992 as part of GSK Global Health, representing the first biopharmaceutical grant-making initiative focused on addressing the AIDS epidemic. Today, Positive Action continues to invest in strategic and community-led partnerships centered on ensuring people living with, and communities affected by, HIV are not left behind.



**2** DELIVER INNOVATIONS THAT RESPOND TO THE NEEDS OF ALL PEOPLE, INCLUDING UNDERSERVED POPULATIONS, AND MAKE THESE AFFORDABLE, ACCESSIBLE, AND SUSTAINABLE

**H3D Partnership:** A unique program on R&D innovation in Africa, H3D focuses on the development of drug discovery technology for diseases that predominantly affect African populations.



**3** HELP STRENGTHEN THE HEALTH WORKFORCE, RESPONDING TO LOCAL CONTEXT, PRIORITIES, AND NEEDS

**EDCTP-TDR Clinical Research Development Fellowships:** A placement program for Sub-Saharan researchers in European pharmaceutical companies to enhance competencies in clinical trials research in low- and middle-income countries.



**4** CONTRIBUTE TO EFFORTS TO RAISE THE FINANCE AVAILABLE FOR UHC

**Access Accelerated:** A long-standing cross-industry collaboration that generates evidence to make the economic case to prioritize efforts against NCDs and its integration within national UHC agendas.



**5** CHAMPION AND ENGAGE IN MULTISTAKEHOLDER POLICY DIALOGUES THAT ADVANCE UHC

**Kigali Declaration on Neglected Tropical Diseases (NTDs):** A commitment uniting governments, pharmaceutical companies, donors, and NGOs to end NTDs by 2030 through country ownership, integration, and cross-sectoral collaboration.



The innovative pharmaceutical industry's partnerships are supported by more than 1100 partners, leveraging the strengths of each player, developing tailored solutions that reflect each country's individual healthcare needs, and laying the groundwork for long-term sustainability.

Explore the full range of our collaborations in Africa and around the world on [Global Health Progress](#) and see how we are working with others to address complex health challenges through coordinated, impact-driven action.

[globalhealthprogress.org](http://globalhealthprogress.org) →

FIND OUT MORE:

[ifpma.org](http://ifpma.org)

[globalhealthprogress.org](http://globalhealthprogress.org)

